LLY

1,054.29

-0.18%↓

JNJ

209.21

-1.51%↓

ABBV

223.95

-0.16%↓

UNH

334.3

-0.78%↓

AZN

90.94

+0.48%↑

LLY

1,054.29

-0.18%↓

JNJ

209.21

-1.51%↓

ABBV

223.95

-0.16%↓

UNH

334.3

-0.78%↓

AZN

90.94

+0.48%↑

LLY

1,054.29

-0.18%↓

JNJ

209.21

-1.51%↓

ABBV

223.95

-0.16%↓

UNH

334.3

-0.78%↓

AZN

90.94

+0.48%↑

LLY

1,054.29

-0.18%↓

JNJ

209.21

-1.51%↓

ABBV

223.95

-0.16%↓

UNH

334.3

-0.78%↓

AZN

90.94

+0.48%↑

LLY

1,054.29

-0.18%↓

JNJ

209.21

-1.51%↓

ABBV

223.95

-0.16%↓

UNH

334.3

-0.78%↓

AZN

90.94

+0.48%↑

Strona główna・Stock List・Fate Therapeutics Inc

Fate Therapeutics Inc

Open

SectorHealthcare

1.1

Buy Sell

Overview

Share price change

24h

Current

Min

1.08

Max

1.13

Key metrics
By Trading Economics
Income	1.8M -32M
Sales	-166K 1.7M
EPS	-0.27
Profit margin	-1,852.384
Employees	181
EBITDA	7.9M -29M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+346.43% upside

Market Stats
By TradingEconomics
Market Cap	-2.3M 123M
Previous open	1.1
Previous close	1.1

News Sentiment

By Acuity

50%

169 / 374 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

0.9101 / 1.14 Support & Resistance

Fate Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

16 gru 2025, 23:46 UTC

Market Talk

Gold Edges Higher, Aided by Fed Rate-Cut Prospects -- Market Talk

16 gru 2025, 23:38 UTC

Market Talk

Nikkei May Rise on Possible Bargain-Hunting Interest -- Market Talk

16 gru 2025, 22:35 UTC

Acquisitions, Mergers, Takeovers

Santos: Sale Delivered Cash, Reduced Future Decommissioning Exposure

16 gru 2025, 22:35 UTC

Acquisitions, Mergers, Takeovers

Santos Sold 43% Stake in Petrel Fields, 100% of Tern Fields to Eni Australia

16 gru 2025, 22:33 UTC

Acquisitions, Mergers, Takeovers

Santos: A$40M Upfront Consideration, Up to A$20M in Contingent Payments

16 gru 2025, 22:33 UTC

Acquisitions, Mergers, Takeovers

Santos Sold 43% Operated Interest in Mahalo JV to Comet Ridge

16 gru 2025, 22:32 UTC

Acquisitions, Mergers, Takeovers

Santos Divests Two Noncore Assets as Part of Portfolio Optimization

16 gru 2025, 22:25 UTC

Acquisitions, Mergers, Takeovers

Westgold's Indicative Timetable Points to Early February Completion

16 gru 2025, 22:24 UTC

Acquisitions, Mergers, Takeovers

Westgold: Divestment Aligns With Broader Corporate Strategy

16 gru 2025, 22:23 UTC

Acquisitions, Mergers, Takeovers

Westgold: Deferred Payment Based on Performance Hurdles

16 gru 2025, 22:23 UTC

Acquisitions, Mergers, Takeovers

Westgold Will Receive A$15M Cash, A$19.6M in Alicanto Shares

16 gru 2025, 22:23 UTC

Acquisitions, Mergers, Takeovers

Westgold to Receive A$30M Deferred Payment in Cash or Shares

16 gru 2025, 22:22 UTC

Acquisitions, Mergers, Takeovers

Westgold Divesting Noncore Operating Asset for A$64.6M

16 gru 2025, 22:22 UTC

Acquisitions, Mergers, Takeovers

Westgold Agrees to Sell Mt Henry-Selene Project to Alicanto Minerals

16 gru 2025, 21:53 UTC

Earnings

Lennar Misses Earnings Estimates. The Stock Is Dropping. -- Barrons.com

16 gru 2025, 21:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

16 gru 2025, 21:33 UTC

Acquisitions, Mergers, Takeovers

Warner Preparing to Tell Shareholders to Reject Paramount Offer -- 2nd Update

16 gru 2025, 21:18 UTC

Acquisitions, Mergers, Takeovers

Warner Preparing to Tell Shareholders to Reject Paramount Offer -- Update

16 gru 2025, 21:17 UTC

Acquisitions, Mergers, Takeovers

Worthington Enterprises to Buy LSI Group for About $205M >WOR

16 gru 2025, 21:16 UTC

Earnings

Worthington Enterprises 2Q Sales $327.5M >WOR

16 gru 2025, 21:16 UTC

Earnings

Worthington Enterprises 2Q Adj EPS 65c >WOR

16 gru 2025, 21:16 UTC

Earnings

Worthington Enterprises 2Q EPS 55c >WOR

16 gru 2025, 21:15 UTC

Acquisitions, Mergers, Takeovers

Worthington Enterprises Agrees To Acquire Leading Metal Roof Components Manufacturer LSI Group >WOR

16 gru 2025, 21:05 UTC

Acquisitions, Mergers, Takeovers

Ecolab Closes Acquisition Of Ovivo's Electronics Ultrapure Water Business >ECL

16 gru 2025, 20:54 UTC

Acquisitions, Mergers, Takeovers

Warner to Reject Paramount Offer As Soon As Wednesday, Sources Say -- WSJ

16 gru 2025, 20:54 UTC

Acquisitions, Mergers, Takeovers

Warner Preparing to Tell Shareholders to Reject Paramount Offer -- WSJ

16 gru 2025, 20:54 UTC

Acquisitions, Mergers, Takeovers

Warner to Recommend Existing Netflix Deal, Sources Say -- WSJ

16 gru 2025, 20:44 UTC

Market Talk

Russia-Ukraine Peace Efforts Send Crude to Near 5-Year Low -- Market Talk

16 gru 2025, 20:04 UTC

Market Talk

U.S. Natural Gas Extends Weather-Driven Losing Streak -- Market Talk

16 gru 2025, 20:01 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

Peer Comparison

Price change

Fate Therapeutics Inc Forecast

Price Target

By TipRanks

346.43% upside

12 Months Forecast

Average 5 USD 346.43%

High 8 USD

Low 2 USD

Based on 8 Wall Street analysts offering 12 month price targets forFate Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

8 ratings

Buy

Hold

Sell

Based on 8 analysts giving stock ratings to Fate Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

0.9101 / 1.14Support & Resistance

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

169 / 374 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.